H.R. 5547 · 118th Congress · House

Maintaining Investments in New Innovation Act

Active· Referred to the Subcommittee on Health.
Introduced
Sep 18, 23
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending

Executive Summary

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

Action Timeline

6
  1. DEC 17, 2024•Committee

    Referred to the Subcommittee on Health.

  2. SEP 22, 2023•Committee

    Referred to the Subcommittee on Health.

  3. SEP 18, 2023•IntroReferral

    Introduced in House

  4. SEP 18, 2023•IntroReferral

    Introduced in House

  5. SEP 18, 2023•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  6. SEP 18, 2023•IntroReferral

    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Committees

4

Health Subcommittee

hswm02

Referred: Dec 17, 2024

Active

Health Subcommittee

hsif14

Referred: Sep 22, 2023

Active

Ways and Means Committee

hswm00

Referred: Sep 18, 2023

Active

Energy and Commerce Committee

hsif00

Referred: Sep 18, 2023

Active